Respiratory Syncytial Virus (RSV) vaccine: PGD template
Patient Group Direction (PGD) template to support the national vaccination programme for pregnant women to protect infants and older adults aged 75 to 79 years old.
- From:
- UK Health Security Agency
- Published
- 29 July 2024
- Last updated
- 17 February 2026 — See all updates
Applies to England
Documents
RSV vaccine Patient Group Direction (PGD)
Ref: UKHSA gateway number GOV-17038GOV-20340
MS Word Document, 214173 KB
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This PGD template supports the administration of the RSV vaccine to:
- women from 28 weeks of pregnancy
- older adults aged 75 to 79 years of age
in accordance with the national programme as outlined in the RSV letter and the RSV Green Book chapter 27a.
The RSV vaccine PGD version 1.00 is valid from 1 September 2024 to 1 April 2027.
Practitioners must not use this template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.
Updates to this page
Published 29 July 2024
Last updated 17 February 2026
href="#full-history">+ show all updates
-
Updated PGD form.
-
First published.
Sign up for emails or print this page
Update history
2026-02-17 16:46
Updated PGD form.
2024-07-29 10:30
First published.
Details
This PGD template supports the administration of the RSV vaccine to:
- women from 28 weeks of pregnancy
- older adults aged 75 to 79 years of age
in accordance with the national programme as outlined in the RSV letter and the RSV Green Book chapter 27a.
The RSV vaccine PGD version 1.00 is valid from 1 September 2024 to 1 April 2027.
Practitioners must not use this template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.
Updates to this page
-
Updated PGD form.
-
First published.
Sign up for emails or print this page
Update history
2026-02-17 16:46
Updated PGD form.
2024-07-29 10:30
First published.